Recent News

• 02.28.2025 - Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
• 02.28.2025 - Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
• 02.19.2025 - Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
• 02.19.2025 - Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
• 02.14.2025 - Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
• 02.14.2025 - Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
• 02.04.2025 - Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
• 02.04.2025 - Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
• 01.31.2025 - Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
• 01.31.2025 - Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Recent Filings

• 02.28.2025 - S-3 Registration statement under Securities Act of 1933
• 02.28.2025 - 8-K Current report
• 02.14.2025 - 8-K Current report
• 02.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2025 - ARS Annual Report to Security Holders
• 02.10.2025 - DEF 14A Other definitive proxy statements
• 02.06.2025 - 4 Statement of changes in beneficial ownership of securities